Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain

References

• Bonica JJ. Importance of the problem. In: Chronic Non-Cancer Pain: Assessment and Practical Management. Anderson SA, Mehta M, Bond MJ (Eds). MTP Press, Lancaster, UK (1987).
   Google Scholar
• Bell GK, Kidd D, North RB. Cost-effectiveness analysis of spinal cord stimulation in treatment of failed back surgery syndrome. J. Pain Symptom Manage.13(5), 286–295 (1997).
   PubMed Web of Science ®Google Scholar
• Frymoyer JW, Cats-Baril WL. An overview of the incidences and costs of low back pain. Orthop. Clin. North Am.22(2), 263–271 (1991).
   PubMed Web of Science ®Google Scholar
• Bennett GJ. Neuropathic pain: new insights, new interventions. Hosp. Pract. (Minneap.)33(10), 95–98, 101–104, 107–110 passim (1998).
   PubMed Web of Science ®Google Scholar
• Katz N. Neuropathic pain in cancer and AIDS. Clin. J. Pain16(Suppl. 2), S41–S48 (2000).
   PubMed Web of Science ®Google Scholar
• Leland JY. Chronic pain: primary care treatment of the older patient. Geriatrics54(1), 23–28, 33–34, 37 (1999).
   PubMed Web of Science ®Google Scholar
• Krames ES. Intraspinal opioid therapy for chronic nonmalignant pain: current practice and clinical guidelines. J. Pain Symptom Manage.11(6), 333–352 (1996).
   PubMed Web of Science ®Google Scholar
• Onofrio BM, Yaksh TL, Arnold PG. Continuous low-dose intrathecal morphine administration in the treatment of chronic pain of malignant origin. Mayo Clin. Proc.56(8), 516–520 (1981).
   PubMed Web of Science ®Google Scholar
• Hassenbusch SJ, Portenoy RK, Cousins M et al. Polyanalgesic Consensus Conference 2003: an update on the management of pain by intraspinal drug delivery – report of an expert panel. J. Pain Symptom Manage.27(6), 540–563 (2004).
   PubMed Web of Science ®Google Scholar
• PRIALT®, package insert. Elan Pharmaceuticals, Inc., San Diego, CA, USA.
   Google Scholar
• Chaplan SR, Pogrel JW, Yaksh TL. Role of voltage-dependent calcium channel subtypes in experimental tactile allodynia.J. Pharmacol. Exp. Ther.269(3), 1117–1123 (1994).
   PubMed Web of Science ®Google Scholar
• Bean BP. Classes of calcium channels in vertebrate cells. Ann. Rev. Physiol.51, 367–384 (1989).
   PubMed Web of Science ®Google Scholar
• Swandulla D, Carbone E, Lux HD. Do calcium channel classifications account for neuronal calcium channel diversity? Trends Neurosci.14(2), 46–51 (1991).
   PubMed Web of Science ®Google Scholar
• Bertolino M, Llinas RR. The central role of voltage-activated and receptor-operated calcium channels in neuronal cells. Ann. Rev. Pharmacol. Toxicol.32, 399–421 (1992).
   PubMed Web of Science ®Google Scholar
• Olivera BM, Miljanich GP, Ramachandran J, Adams ME. Calcium channel diversity and neurotransmitter release: the omega-conotoxins and omega-agatoxins. Ann. Rev. Biochem.63, 823–867 (1994).
   PubMed Web of Science ®Google Scholar
• Dunlap K, Luebke JI, Turner TJ. Exocytotic Ca2+ channels in mammalian central neurons. Trends Neurosci.18(2), 89–98 (1995).
   PubMed Web of Science ®Google Scholar
• Vanegas H, Schaible H. Effects of antagonists to high-threshold calcium channels upon spinal mechanisms of pain, hyperalgesia and allodynia. Pain85(1–2), 9–18 (2000).
   PubMed Web of Science ®Google Scholar
• Olivera BM, Cruz LJ, de Santos V et al. Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom. Biochemistry26(8), 2086–2090 (1987).
   PubMed Web of Science ®Google Scholar
• Miljanich GP, Ramachandran J. Antagonists of neuronal calcium channels: structure, function, and therapeutic implications. Ann. Rev. Pharmacol. Toxicol.35, 707–734 (1995).
   PubMed Web of Science ®Google Scholar
• Wang Y-X, Bowersox SS. Analgesic properties of ziconotide, a selective blocker of N-type neuronal calcium channels. CNS Drug Rev.6(1), 1–20 (2000).
   Google Scholar
• Ridgeway B, Wallace M, Gerayli A. Ziconotide for the treatment of severe spasticity after spinal cord injury. Pain85(1–2), 287–289 (2000).
   PubMed Web of Science ®Google Scholar
• Wermeling D, Drass M, Ellis D et al. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients. J. Clin. Pharmacol.43(6), 624–636 (2003).
   PubMed Web of Science ®Google Scholar
• Staats PS, Yearwood T, Charapata SG et al. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. JAMA291(1), 63–70 (2004).
   PubMed Web of Science ®Google Scholar
• Wallace MS, Charapata SG, Fisher R et al. Intrathecal ziconotide in the treatment of chronic nonmalignant pain: a randomized, double-blind, placebo-controlled clinical trial. Neuromodulation9(2), 75–86 (2006).
   PubMed Web of Science ®Google Scholar
• Rauck RL, Wallace MS, Leong MS et al. A randomized, double-blind, placebo-controlled study of intrathecal ziconotide in adults with severe chronic pain. J. Pain Symptom Manage.31(5), 393–406 (2006).
   PubMed Web of Science ®Google Scholar
• Atanassoff PG, Hartmannsgruber MW, Thrasher J et al. Ziconotide, a new N-type calcium channel blocker, administered intrathecally for acute postoperative pain. Reg. Anesth. Pain Med.25(3), 274–278 (2000).
   PubMed Web of Science ®Google Scholar
• Wallace MS, Yaksh TL. Long-term intraspinal drug therapy: a review. Reg. Anesth. Pain Med.25, 117–157 (2000).
   PubMed Web of Science ®Google Scholar